Catalyst Clinical Trial Presentation

225 Dunn Street,Houma LA 70360

21 September, 2022

Description

Introducing the Catalyst TrialJoin us for a presentation with Drs. Peter Fail & Shane Prejean to learn about an investigational procedure for patients with non-valvular atrial fibrillation. Refreshments will be provided. Registration is required. Please reserve your spot here or call (985) 875-5058 with any questions. ELIGIBLE PATIENTS • A documented history of non-valvular atrial fibrillation • CHA2DS2-VASc score ≥ 3 • Eligible for long-term NOAC therapy The CATALYST Trial will compare treatment with Abbott’s Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treatment with non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation at high-risk for stroke. PROCEDURE OVERVIEW Subjects will be randomized 1:1 to receive the Amplatzer Amulet Left Atrial Appendage Occluder or NOAC therapy in the CATALYST Trial. The Amulet occluder is delivered in a minimally invasive transcatheter approach through a femoral venous puncture. The Amulet occluder is introduced to the left atrium via an interatrial transseptal puncture. The lobe secures the Amulet occluder within the left atrial appendage, while the disc completely seals the appendage at the orifice.